Samphire Neuroscience
PrivateLast Round
Seed
Jun 3, 2025
Total Funding Raised
$7.3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Samphire Neuroscience operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Seed round in June 2025.
Samphire Neuroscience is a healthtech company that develops non-invasive, brain-stimulating wearable devices and a companion mobile application to alleviate symptoms associated with the menstrual cycle.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Mental Health, Health IoT
Business Model
B2C
Customer Profile
Hardware Sales, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Samphire Neuroscience Comparables
Compare Samphire Neuroscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Yuthera | 88% | |
| Spark Biomedical Inc | 83% | |
| Myoovi | 83% |
For institutional investors. Book with your work email.
Samphire Neuroscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jun 3, 2025 | ||||
| Pre Seed | Feb 21, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Samphire Neuroscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ayuh Ventures | Seed, Pre Seed |
| APEX Capital | Seed |
| AfterWork Ventures | Seed, Pre Seed |
| Inventure | Seed |
| FIRSTPICK | Seed, Pre Seed |
| CVX Ventures | Pre Seed |
| Seaside Ventures | Seed, Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 58% MoM.
- Jul 1, 2026
CREST26 pivotal US trial has officially begun.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 6, 2026
Samphire Neuroscience announces that its headband for at-home brain stimulation, which applies gentle electric current through the scalp, can now manage PMDD-related anxiety symptoms in the United Kingdom and European Union on Nov 5th '26.
For institutional investors. Book with your work email.
Samphire Neuroscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Samphire Neuroscience's valuation, stock price, and market status.
Is Samphire Neuroscience a public or private company?
Samphire Neuroscience is a private company.
What is the current stock price of Samphire Neuroscience?
Samphire Neuroscience is a private company, so its shares have no public market price. Caplight tracks Samphire Neuroscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Samphire Neuroscience worth (valuation)?
Valuation information for Samphire Neuroscience is not publicly available.
Can I buy Samphire Neuroscience stock?
Samphire Neuroscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Samphire Neuroscience's last funding round?
Samphire Neuroscience's most recent funding round was Seed on June 3, 2025.
Who are the main investors in Samphire Neuroscience?
Key investors in Samphire Neuroscience include Inventure, Fortify Ventures.
Will Samphire Neuroscience IPO soon?
No public IPO plans have been announced for Samphire Neuroscience.
How can I track Samphire Neuroscience secondary market activity?
Caplight tracks bids, offers, and trades in Samphire Neuroscience's shares on secondary markets.